A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study Evaluating the Efficacy and Safety of HS-10353 in Chinese Adults With Depression.
Latest Information Update: 13 Jul 2023
At a glance
- Drugs HS 10353 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 12 Jul 2023 New trial record